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 Abstract 
 This study has been designed to evaluate the impact of adiponectin levels on left ventricular geometry and function in 
visceral obesity-associated hypertension. 94 consecutive subjects, 53 of them were hypertensives and 41 normotensives 
with age    65 years, subgrouped according to the presence or absence of visceral obesity, were studied. Total adiponec-
tin levels were measured by a validated competitive radioimmunoassay. Left ventricular telediastolic internal diameter, 
interventricular septum, posterior wall thickness, total left ventricular mass (LVM) and normalized for height to the 2.7 
power (LVM/h 2.7 ), relative wall thickness, left ventricular ejection fraction by echocardiography and isovolumic relaxation 
time, E/A ratio and deceleration time of E velocity, by pulsed-wave Doppler, were calculated. Plasma adiponectin levels 
were signifi cantly lower in visceral obesity-associated hypertensives than lean hypertensives ( p    0.001) and in lean nor-
motensives ( p    0.001). LVM and LVM/h 2.7 were signifi cantly ( p    0.05) higher in both hypertensive groups, and in 
visceral obesity-associated normotensives in comparison with lean normotensives. Adiponectin levels correlated inversely 
with LVM/h 2.7 but only in normotensives (adjusted  R squared 0.77,  p    0.0001) and hypertensives (0.67,  p    0.0001) 
subjects with visceral obesity. Multiple regression analysis indicated that adiponectin levels remain signifi cantly associated 
( p    0.001) to LVM/h 2.7 also when adjusted for age, gender, body mass index, waist to hip ratio and mean blood pres-
sure. Our data suggest an important role of adiponectin in increased LVM/h 2.7 in visceral obesity-associated normoten-
sive and hypertensive subjects. In this last group, adiponectin, more than blood pressure, may be able to explain the 
development of cardiac damage. 
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 Introduction 
 Cardiovascular protection is one of the most impor-
tant goals of antihypertensive treatment (1). On the 
other hand, obesity, especially when characterized by 
visceral fat distribution, is often associated with 
hypertension and overall mortality (2). In fact, for 
many years, it has been well demonstrated that obese 
patients with visceral fat distribution are more likely 
to be hypertensive than lean subjects, and that weight 
gain is predictive of earlier onset of hypertension. In 
addition, the association of visceral obesity and 
hypertension seems to confer a higher cardiovascular 
risk than that detectable in lean hypertensives (2 – 4). 
This association is characterized by adverse morpho-
logic and functional changes in the cardiovascular 
system. They include an increased left ventricular 
mass (LVM) and early left ventricular (LV) dysfunc-
tion (5,6). Although changes in the heart caused by 
hypertension and/or visceral obesity are well known, 
the effective mechanisms are not. Despite largely 
emphasized hemodynamic effects and growth fac-
tors, other metabolic and infl ammatory factors exist. 
In view of this, an increase in LVM might occur inde-
pendently of blood pressure (7). Accordingly, we 
have previously recognized some clinical predictors 
of LV hypertrophy (LVH) in obese hypertensive 
patients, such as the concomitant presence of a pos-
itive family history of both hypertension and visceral 
obesity (8) and an overproduction of transforming 
growth factor beta2 (9). 
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2 T. Di Chiara et al. 
 In addition, it is now known that adipocytes are 
active endocrine and paracrine cells secreting an 
increasing number of mediators called  “ adipo-
citokynes ” , including adiponectin, a collagen-like pro-
tein abundantly produced in adipose tissue that plays 
an important role in the modulation of glucose and 
lipid metabolism (10,11). It has been demonstrated 
that adiponectin has several antiatherogenic and antid-
iabetic properties. Lower levels of adiponectin are asso-
ciated with higher risk of myocardial infarction (12), 
with increased carotid atherosclerosis (13) and with 
vulnerability of coronary plaque (14). Lower levels of 
adiponectin have been also reported in some condi-
tions associated with insulin resistance, such as visceral 
obesity, hypertension and diabetes (10,11,15,16). 
 Receptors of adiponectin are expressed in cul-
tured cardiac myocytes and heart tissue, and experi-
mental evidences suggest that adiponectin inhibits 
hypertrophic signaling in the myocardium and may 
thus infl uence cardiac remodeling (10,11,17 – 19). 
 Despite these data, the role of adiponectin on car-
diac changes occurring in visceral obesity-associated 
hypertension has not been investigated. 
 The present study has been designed to evaluate 
the impact of adiponectin levels on LV geometry and 
function in visceral obesity-associated hypertension. 
Accordingly, plasma levels of adiponectin and their 
relationships with measurements of LV geometry 
and function have been analyzed in normotensive 
and hypertensive both lean and visceral obese sub-
jects. The main goal of the study was to evaluate the 
role of adiponectin in the cardiac changes occurring 
in both hypertensive and normotensive visceral 
obese subjects. 
 Subjects and methods 
 Subjects 
 Subjects eligible for the study were screened at the 
center of hypertension and metabolic disease at the 
Department of Internal Medicine, University of Pal-
ermo (Italy). The study population consisted of 94 
consecutive subjects; 53 of them were hypertensives 
and 41 normotensives with age    65 years. Each 
patient gave a written consent after received a detailed 
description of study procedure. The study was 
approved by ethics committee of our institution. All 
participants underwent a standardized examination 
that included interviews, anthropometry, BP mea-
surements, resting electrocardiogram, Doppler 
echocardiography and a fasting blood draw. 
 Information regarding medical history, drug use, 
alcohol and cigarette consumption was collected 
during a face-to-face interview using a standardized 
questionnaire. Height was measured on a clinic sta-
diometer. Body weight was measured by electrical 
bioimpedance using a body composition analyzer 
model TB-300 (Tanita, Tokyo, Japan). Body mass 
index (BMI) was calculated. Waist circumference was 
measured by plastic tape as the narrowest circumfer-
ence between the lower rib margin and anterior supe-
rior iliac crest. Brachial BP was measured three times 
during three different visits, with a standard sphyg-
momanometer after 5 min of rest. The mean value 
was used in statistical analysis. 
 The subjects were defi ned as obese on the basis 
of sex-specifi c 85th percentile of BMI values, as 
reported in the Italian Consensus Conference on 
Obesity (20). Accordingly, the men with BMI higher 
than or equal to 30 kg/m 2 and the women with BMI 
higher than or equal to 27.3 kg/m 2 were considered 
obese. Conversely, the men with BMI less than or 
equal to 25 kg/m 2 and the women with BMI less than 
or equal to 24.7 kg/m 2 were considered lean. Visceral 
fat distribution was defi ned on the basis of sex-spe-
cifi c 85th percentile of waist to hip ratio (WHR). The 
cut-off values of visceral obesity were considered 
0.81 for women and 0.92 for men (21). 
 Subjects under antihypertensive treatment or with 
a casual blood pressure (SBP)    140 mmHg and/or 
with casual diastolic blood pressure (DBP)    90 
mmHg were considered hypertensives. Arterial blood 
pressure was measured with an appropriate large cuff 
in obese subjects. Systolic (SBP), diastolic (DBP) and 
mean blood pressure (MBP) were determined. MBP 
was calculated by the sum of DBP plus one third of 
pulse pressure. All the hypertensives were untreated 
for at least 3 weeks before the study. Lean normoten-
sives were volunteer subjects by us recruited to undergo 
a clinical check-up and found to be healthy. 
 Exclusion criteria included severe hypertension, 
cardiovascular diseases, renal failure, insulin-depen-
dent or -independent diabetes mellitus, hyperlipo-
proteinemia, electrolyte imbalance, smoking habit 
and alcoholism, or psychiatric problems. 
 All the subjects included in this study were 
subdivided as follows: 
 (1) Lean normotensives: this group consisted of 15 
subjects (six females and nine males, mean age 
46.5    13.3 years); 
 (2) Visceral obese normotensives: this group con-
sisted of 26 subjects (12 females and 14 males; 
mean age 52.1    8.4 years); 
 (3) Lean hypertensives: this group consisted of 17 
subjects (eight females and nine males; mean 
age 49.2    7.5 years); 
 (4) Visceral obese hypertensives: this group consisted 
of 36 subjects (16 females and 20 males; mean 
age 51.0    9.2 years). 
 Biochemical measurements 
 Patients underwent a general analytical laboratory 
parameters profi le including BUN, creatinine and 
clearance, glycemia, electrolytes and cholesterol, by 
routine laboratory methods. 
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  Adiponectin and left ventricular mass  3
 Peripheral venous blood was obtained from each 
patient and the sera were isolated and stored at 
   70 ° C. Total adiponectin levels were measured by 
a validated competitive radioimmunoassay (Linco 
Research Inc., St Charles, MO) with a coeffi cient of 
variation of 3.4%. In a previous analysis, adiponec-
tin levels had excellent intraclass correlation coeffi -
cient measured in participants over a period of 1 
year and were not substantially affected by transport 
conditions (22). 
 Echocardiographic measurements 
 All patients underwent an echocardiography exam-
ination M and B-mode, by a computerized echocar-
diography (ESAOTE, Italy) for the determination 
of following parameters: LV telediastolic internal 
diameter (LVIDd), interventricular septum (IVSTd), 
and posterior wall thickness (PWTd). The Penn con-
vention was used to calculate LVM. LVM was nor-
malized for height to the 2.7 power (LVM/h 2.7 ) 
(7,23). Accordingly, all the hypertensives with 
LVM/h 2.7    50 g/m 2.7 for men and    47 g/m 2.7 for 
women were considered to have LVH. The relative 
wall thickness (RWT) by formula [(PWTd/
LVIDd)   2] was also calculated. Ejection fraction 
from LV end-diastolic and end-systolic volumes 
was measured from the apical four-chamber view, 
using the ellipsoidal single-plane algorithm. Mean 
ejection fraction was automatically calculated by 
the echocardiographic processing system. In our 
laboratory, the ejection fraction calculated over fi ve 
consecutive beats permitted optimal reproducibility 
and accuracy (23). 
 LV relaxation and fi lling were evaluated by pulsed-
wave Doppler interrogation of the LV infl ow tract 
from the apical four-chamber view, with the sample 
volume placed at the tips of the mitral valve. After a 
stable signal of the transmitral fl ow velocity was 
obtained, the Doppler cursor was moved toward the 
LV outfl ow tract in the apical fi ve-chamber view for 
recording both mitral and aortic signals, including 
the closing click of the aortic valve and the opening 
click of the mitral valve. Doppler signals were 
recorded at high speed (80 – 120 mm/s) with the sub-
jects in held expiration. An average of fi ve beats was 
used for analysis. 
 Isovolumic relaxation time (IVRT) was calcu-
lated as the time from the closure click of the aortic 
valve to the opening click of the mitral valve. When 
either the closing or opening click was not identifi ed, 
the time from the end of the aortic fl ow to the onset 
of mitral fl ow from the continuous wave interroga-
tion of the LV infl ow – outfl ow tract was used. Peak 
early transmitral fl ow velocity (E), peak late transmi-
tral fl ow velocity (A) and the deceleration time of E 
velocity (DTE) were measured at the tips of mitral 
leafl ets at the maximum amplitude of E velocity. 
DTE was measured as the time from peak E velocity 
to the time when the E wave descent intercepts the 
zero line. 
 Statistical analysis 
 Data are shown as mean   SD: the chi-square and 
the Fisher exact test were used for contingency table 
analysis. To explore for statistical signifi cant differ-
ences, one-way ANOVA was performed with Bonfer-
roni connection  post hoc analysis for comparison 
between groups. Multivariate linear regression analy-
sis was performed to study relationship among inde-
pendent variables and LVM/h 2.7 .  The best prediction 
model was build after a bivariate analysis. A  p -value 
of 0.25 was used as cut-off for variable inclusion into 
the model. The fi nal model was build with a back-
ward selection of variables until the  p -value of each 
variable into the model was inferior to 0.25. We used 
a bootstrap procedure (50 replications per time) to 
validate the regression model and compute standard 
errors. Multiple fractional polynomial analysis was 
performed to study the best power fi t between each 
independent variable and the dependent ones. Linear 
regression lines and their confi dence intervals were 
computed by conventional methods for visual repre-
sentations. STAT/SE, version 9.2 for Windows 
(StataCorp. College Station, Texas), was used to both 
analyze and graph the data. 
 Results 
 Characteristics of lean and visceral obese groups 
 All the groups were comparable with regard to sex 
and age. Lean and visceral obese normotensives and 
hypertensives were also comparable with regard to 
systolic, diastolic and mean blood pressure. Both 
lean and visceral obese groups were also comparable 
accordingly to BMI and WHR values. Plasma adi-
ponectin levels were signifi cantly lower in visceral 
obese hypertensives than those detectable both in 
lean hypertensives ( p    0.001) and in lean normoten-
sives ( p    0.001). In addition, adiponectin levels were 
lower but not signifi cantly, both in visceral obese 
hypertensives respect to visceral obese normoten-
sives and in lean hypertensives in comparison with 
lean normotensives (Table I). 
 No signifi cant difference in adiponectin levels 
were detected in all the groups subdivided according 
to gender (Table II). 
 Echocardiographic measurements 
 LVM and LVM/h 2.7 values were signifi cantly 
( p    0.05) higher in visceral obese hypertensives, in 
lean hypertensives and in visceral obese normoten-
sives in comparison with lean normotensives. No 
signifi cant changes in remain cardiac measurements 
among the groups were found (Table III). 
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 Correlations 
 Linear regression analysis demonstrated that adi-
ponectin levels correlated inversely with LVM/h 2.7 
but only in normotensive (adjusted  R squared 0.77; 
 p    0.0001) and hypertensive visceral obese partici-
pants (adjusted  R squared 0.67;  p    0.0001) 
(Figure 1). This relationship remained signifi cant 
(adjusted  R squared 0.72;  p    0.0001) even when 
visceral obese normotensives and hypertensives were 
analyzed together (Figure 2). 
 In all the subjects studied, multiple regression 
analysis indicated that adiponectin levels remained 
signifi cantly ( p    0.001) associated with LVM/h 2.7 
also when adjusted for age, gender, BMI, WHR and 
MBP (Table IV). 
 Discussion and conclusions 
 To our knowledge, this is the fi rst study able to indi-
cate the relevant role of adiponectin to explain the 
changes in cardiac geometry in visceral obese sub-
jects both hypertensive and normotensive. In fact, 
the main data of our study suggest that visceral obese 
subjects both normotensive and hypertensive had 
 Table I. Clinical characteristics and adiponectin levels in normotensive and hypertensive lean and visceral 
obese subjects. 
Normotensives Hypertensives
Lean, 
 n  	  15
Visceral obese, 
 n  	  26
Lean, 
 n  	  17
Visceral obese, 
 n  	  36
Sex (F/M) 6/9 12/14 8/9 16/20
Age (yr) 46.5    13.3 52.1    8.4 49.2    7.5 51.0    9.2
BMI (kg/m 2 ) 22.4    1.7 31.6    3.2 * a 24.3    0.5 31.3    20.9 * a 
WHR (%) 0.84    0.05 0.95    0.07 * a 0.82    0.06 0.96    0.06 * a 
SBP (mmHg) 128.7    6.7 128.8    8.7 151.2    7.6 * b 154.9    8.5 * b 
DBP (mmHg) 78.3    4.5 78.8    5.2 94.4    5.8 * b 96.0    7.4 * b 
MBP (mmHg) 95.1    4.2 95.4    5.2 113.2    4.6 * b 115.3    5.9 * b 
Adiponectin (ng/ml) 11.2    1.05 7.1    1.3 * a 11.6    0.7 6.7    1.7 * a 
 F, females; M, males; BMI, body mass index; WHR, waist – hip ratio; SBP, systolic blood pressure; DBP, 
diastolic blood pressure; MBP, mean blood pressure. One-way analysis of variance:  * p    0.001 vs lean 
normotensives;  a p    0.001 vs lean hypertensives;  b p    0.001 vs visceral obese normotensives. 
 Table II. Plasma adiponectin levels in all the groups subdivided according to gender. a 
Normotensives,  n  	  41 Hypertensives,  n  	  53
Lean,  n  	  15 Visceral obese,  n  	  26 Lean,  n  	  17 Visceral obese,  n  	  36
Sex (male   female)  n  	  9  n  	  6  n  	  14  n  	  12  n  	  9  n  	  8  n  	  20  n  	  16
Adiponectin (ng/ml) 11.2    0.9 11.3    1.1 7    1.0 7.2    1.3 11.4    0.6 11.8    0.8 6.5    1.5 6.8    1.8
 a In all the groups the differences in adiponectin levels between males and females were statistically not signifi cant. 
 Table III. Echocardiographic measurements in normotensive and hypertensive lean and visceral 
obese subjects. 
Normotensives Hypertensives
Lean, 
 n  	  15
Visceral obese, 
 n  	  26
Lean, 
 n  	  17
Visceral obese, 
 n  	  36
LVM (g) 153.9    43.8 160.3    31.2 * 175.3    38.7 * 174.8    46.2 * 
LVM/h 2.7 (g/h 2.7 ) 36.6    5.9 42.3    8.4 43.4    11.2 44.4    11.5
LVID/h (mm/h) 2.78    0.20 2.93    0.17 2.89    0.17 2.89    0.25
IVST (mm) 9.3    1.30 9.6    1.0 10.1    1.40 9.9    2.2
RWT 0.42    0.10 0.39    0.05 0.40    0.06 0.38    0.05
LVEF (%) 64.7    2.2 64.4    2.7 64.7    3.1 63.8    3.0
E/A 1.5    0.2 1.4    0.3 1.4    0.2 1.2    0.3
DTE (ms) 199    35 202    40 201    39 205    41
IVRT (ms) 80    12 79    10 81    11 80    10
 LVM, left ventricular mass; LVM/h 2.7 , left ventricular mass/height 2.7 ; LVID/h, left ventricular internal 
diameter/height; IVST, interventricular septal thickness; RWT, relative wall thickness; LVEF, left ven-
tricular ejection fraction; E/A, peak early transmitral fl ow/peak late transmitral fl ow; DTE, E deceleration 
time; IVRT, isovolumic relaxation time. One-way analysis of variance:  * p    0.05 vs lean normotensives. 
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  Adiponectin and left ventricular mass  5
lower serum adiponectin levels and higher levels of 
LVM/h 2.7 , than those detectable respectively in lean 
normotensive and in lean hypertensive subjects. In 
addition, systolic and diastolic function seems to be 
preserved in all the groups. Furthermore, data from 
multiple regression analysis indicated a signifi cant 
inverse relationship between LVM/h 2.7 and serum 
adiponectin levels but only in both visceral obese 
groups. This association was independent of age, 
gender, BMI and MBP. This fi nding appears interest-
ing, indicating that adiponectin might be considered 
an important factor associated with changes in 
cardiac geometry in normotensive and hypertensive 
visceral obese subjects. Adiponectin levels seem to be 
more important than blood pressure in the recogniz-
ing of LVH in visceral obese hypertensives. In our 
opinion, the lack of abnormalities in diastolic func-
tion might be explained by the age of patients stud-
ied. Accordingly, the increased values of indexed 
LVM by us found might be considered an early 
cardiac alteration in these subjects. 
 The relation between hypoadiponectinemia and 
the risk of hypertension is well known (24). Several 
cross-sectional studies had previous shown an 
inverse relation between adiponectin levels and 
MBP (25,26). Recently, Chow et  al. (27) added 
another important observation to the relationship 
between adipose tissue and high BP, by demonstrat-
ing, for the fi rst time, an inverse relation between 
plasma adiponectin concentration and the future 
development of hypertension. In this study, a low 
serum adiponectin level at baseline was a powerful 
predictor of future hypertension. Moreover, hypoa-
diponectinemia has been reported to contribute to 
the development of obesity-related hypertension at 
least in part directly, in addition to its effects through 
insulin resistance (28). 
 On the other hand, it is known that LVH is 
very frequent in obese subjects (3,4,29). The 
increased metabolic needs accompanying obesity 
cause hyperdynamic circulation as the blood volume 
increases. Additionally, peripheral vascular resistance 
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 Figure 1. Correlation between plasma adiponectin levels and indexed left ventricular mass in all the groups studied. 
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 Figure 2. Correlation between plasma adiponectin levels and 
indexed left ventricular mass in both groups of obese subjects. 
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6 T. Di Chiara et al. 
and increased vascular stiffness are developed, lead-
ing to hemodynamic overload. Consequently, an 
increase in LVM may be expected (2,3,30). How-
ever, the common belief is that the infl uential mech-
anisms are not limited to hemodynamic changes. In 
fact, a large population-based study has shown that 
only about 50% of LVM variation can be explained 
by demographic and hemodynamic factors (31). 
Thus, non-hemodynamic mechanisms are likely to 
contribute to increase in LVM and wall thickness 
(WT). In this fi eld, an important role has been 
recently attributed to visceral obesity (2,3,8,32). 
 The negative relation between adiponectin and 
LVM/h 2.7 found by us in normotensive and hyper-
tensive visceral obese subjects may also contribute to 
this mechanism. In other words, in these subjects a 
lack of protective effects of adiponectin may cause 
an increase in LVM/h 2.7 . Our data are in agreement 
with results from previous studies indicating that 
serum adiponectin is inversely and independently 
associated also with electrocardiographically diag-
nosed LVH (19), and that adiponectin is able to 
infl uence cardiac remodeling (33). It has been shown 
experimentally that decreased plasma adiponectin 
levels may lead to LVH by directly affecting LVM, 
and that an increase in adiponectin levels may be 
effective in correcting the pathologic change in car-
diac structure (18). Accordingly, adiponectin admin-
istration might have a practical clinical application to 
restore LVH (34). 
 In our study, hypertension might be considered 
a confounding factor, since it could cause both LVH 
and may be associated with reduction in adiponec-
tin levels. For these reasons, we have studied lean 
and visceral obese subjects, both normotensive and 
hypertensive. Results from our multiple regression 
analysis indicated an independent association 
between low adiponectin levels and higher LVM/
h 2.7 values, which might contribute to clarify this 
question. Accordingly, in our opinion, it is possible 
to suggest that when we study the relationships 
between adipocytokines and hypertension, we must 
simultaneously evaluate the presence or absence of 
visceral obesity. 
 Several mechanisms have been suggested to 
explain the hypothesis that hypoadiponectinemia 
may cause LVH. A possible effect of adiponectin on 
LVM may be to inhibit hypertrophic signaling directly 
in the myocardium by activating adenosine mono-
phosphate-activated kinase, which activates eukary-
otic elongation factor-2 kinase and the inhibitor of 
cardiac myocyte protein synthesis (18,19). 
 Another possible mechanism may be the suppres-
sion of angiotensin II-stimulated myocyte hypertro-
phy with adiponectin (35), but our study is not 
suffi cient to explain these mechanisms because of its 
cross-section design. However, the presence of a 
negative relationship between adiponectin and LVM/
h 2.7 also in visceral obesity without hypertension 
might suggest that decreased myocardial protein syn-
thesis via the inhibition of hypertrophic signaling 
may play a more important role in explaining adi-
ponectin-associated myocardial protection. 
 There are some limitations to our study. In 
fact, it has been designed to be a cross-sectional 
study. Evaluation of the cause-effect relationship 
between hypoadiponectinemia and LVH would 
require a prospective study design with a cohort 
base and larger numbers of cases. Therefore, we 
cannot prove causality or predictive ability, but only 
discern association. 
 In conclusion, the present study indicates that 
decreased adiponectin plasma levels were associated 
with increased LVM/h 2.7 values in normotensive and 
hypertensive visceral obese subjects. In this particu-
lar subgroup of hypertensives, characterized by the 
contemporaneous presence of visceral obesity, adi-
ponectin, more than blood pressure, is able to explain 
the development of cardiac damage. Accordingly, 
also considering that the protective role of adiponec-
tin in CVD is still controversial (36), clinical long-
term follow-up with a large number of participants 
is needed to validate this hypothesis, evaluating 
whether the increase in adiponectin levels induced 
by antihypertensive therapy might be able to improve 
LV geometry. Accordingly, in this particular sub-
group of hypertensive subjects with visceral obesity, 
adiponectin levels might become a new target of 
antihypertensive treatment. 
 Declaration of interest: The authors report no 
confl icts of interest. The authors alone are respon-
sible for the content and writing of the paper. 
 Table IV. Multiple regression analysis. 
LVM/h 2.7 Coeffi cients  t  p 95% CI
Adiponectin    2.837456    5.34    0.001    3.894 to 1.780
age    0.1363836 1.52   	  0.132    0.0417 to 0.3145
BMI 0.1858286 0.57   	  0.573    0.4689 to 0.8385
WHR    68.98193    3.85    0.001    104.5 to 33.41
MBP 0.1977732 2.59   	  0.011 0.04580 to 0.3497
Gender 7.525158 3.25   	  0.002 2.928 to 12.121
 LVM/h 2.7 , left ventricular mass/height 2.7 ; BMI, body mass index; WHR, waist – hip ratio; MBP, mean 
blood pressure; CI, confi dence interval. 
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